PHILADELPHIA, PA - Adaptimmune Therapeutics plc (NASDAQ: NASDAQ:ADAP), a leader in cell therapy for solid tumors, has announced that Cintia Piccina will return as Chief Commercial Officer starting March 18, 2024.
Piccina previously held the position from January 2022 to March 2023 and will now guide the commercial team through the anticipated launch of afami-cel, a potential first-in-class engineered TCR T-cell therapy for advanced synovial sarcoma.
Adaptimmune's CEO, Adrian Rawcliffe, expressed confidence in Piccina's expertise in cell therapy commercialization, which will be crucial as the company approaches the PDUFA date for afami-cel on August 4, 2024. Rawcliffe highlighted Piccina's significant role in developing Adaptimmune's commercial strategy and preparing for the upcoming product launch.
Piccina shared her enthusiasm for rejoining Adaptimmune and contributing to the commercialization of afami-cel, aiming to provide new treatments for advanced cancer patients. Her recent role as Chief Commercial Officer at AlloVir (NASDAQ: ALVR) and previous experience at Bluebird Bio (NASDAQ:BLUE) (NASDAQ: BLBD) / 2seventy Bio (NASDAQ: TSVT) and Novartis (SIX: SIX:NOVN) (NYSE: NVS) have equipped her with extensive knowledge in the field.
Afami-cel, targeting the MAGE A4 cancer antigen, is designed as a single-dose treatment and has shown promising clinical responses in the SPEARHEAD-1 trial. The therapy's Biologics License Application (BLA) received priority review by the FDA, with the agency's decision expected by early August.
The reappointment of Piccina is part of Adaptimmune's strategic preparations for the potential market entry of afami-cel, which would mark a significant advancement in the treatment of synovial sarcoma, a condition that has not seen a new FDA-approved therapy since 2012.
This news is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.